Cosimo Zaccaria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cosimo Zaccaria has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Loris Piccolo
European Medicines Agency, Amsterdam, Netherlands
2 shared publications - María Gordillo-Marañón
Division of Real‐World Data and Pharmacoepidemiology, Medicines for Human Use Department Spanish Agency of Medicines and Medical Devices (AEMPS) Madrid Spain
2 shared publications - Agnieszka Szmigiel
Pharmacovigilance Office, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS, Amsterdam, The Netherlands.
1 shared publication - Bénédicte Cappelli
European Medicines Agency, Pharmacovigilance Office, Amsterdam, The Netherlands
1 shared publication - Catherine Cohet
GSK Vaccines, Wavre, Belgium
1 shared publication - Corinne de Vries
European Medicines Agency, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
Comparing Existing Algorithms for Retrieving Pregnancy-related Adverse Event Reports
Background: Post-marketing surveillance is essential for complementing the safety profiles of medicinal products, especially for populations generally excluded from clinical trials such as pregnant individuals. However, the absence of a standardised pregnancy indicator in the electronic transmissions of adverse event reports hampers their correct identification in pharmacovigilance databases and complicates the study of safety concerns related to pregnancy exposures. Three recently developed rule-based algorithms with the common aim to systematically retrieve pregnancy-related reports differ in scope and are tailored to different databases (A. FAERS, B. EudraVigilance, C. VigiBase). Aim: To compare the design and outputs of the three pregnancy algorithms. Methods: This study was a collaboration among the authors of the three pregnancy algorithms. We harmonised their rules, implemented them in an R package to enable execution in both VigiBase and FAERS, and analysed key characteristics of reports flagged by each algorithm. Results: The pregnancy algorithms A, B, and C flagged 235653, 279515, and 446957 reports respectively in VigiBase, and 265015, 260734, 350479 in FAERS. Reports exclusively retrieved by each algorithm (994, 3248, and 142324 in VigiBase, and 1528, 1100, and 59643 in FAERS) were mostly explained by Algorithm A having no age restriction, Algorithm B excluding normal pregnancy and ineffective contraception, and Algorithm C excluding paternal exposure. Conclusions: Differences in flagging were largely related to varying scopes. Understanding commonalities and differences is crucial for empowering professionals working with pregnancy-related pharmacovigilance to select and use the most appropriate algorithm for their specific needs. Key points: Three independently developed algorithms were designed to retrieve pregnancy-related adverse event reports and support research into pregnancy-specific safety concerns. By applying these algorithms to VigiBase and FAERS, we highlighted overlaps and differences in the reports they flag, reflecting heterogeneous scope and implementation. Awareness of these distinctions is essential to select and apply the most suitable algorithm for their specific needs.
Open AccessComparing Existing Algorithms for Retrieving Pregnancy-related Adverse Event Reports
Background: Post-marketing surveillance is essential for complementing the safety profiles of medicinal products, especially for populations generally excluded from clinical trials such as pregnant individuals. However, the absence of a standardised pregnancy indicator in the electronic transmissions of adverse event reports hampers their correct identification in pharmacovigilance databases and complicates the study of safety concerns related to pregnancy exposures. Three recently developed rule-based algorithms with the common aim to systematically retrieve pregnancy-related reports differ in scope and are tailored to different databases (A. FAERS, B. EudraVigilance, C. VigiBase). Aim: To compare the design and outputs of the three pregnancy algorithms. Methods: This study was a collaboration among the authors of the three pregnancy algorithms. We harmonised their rules, implemented them in an R package to enable execution in both VigiBase and FAERS, and analysed key characteristics of reports flagged by each algorithm. Results: The pregnancy algorithms A, B, and C flagged 235653, 279515, and 446957 reports respectively in VigiBase, and 265015, 260734, 350479 in FAERS. Reports exclusively retrieved by each algorithm (994, 3248, and 142324 in VigiBase, and 1528, 1100, and 59643 in FAERS) were mostly explained by Algorithm A having no age restriction, Algorithm B excluding normal pregnancy and ineffective contraception, and Algorithm C excluding paternal exposure. Conclusions: Differences in flagging were largely related to varying scopes. Understanding commonalities and differences is crucial for empowering professionals working with pregnancy-related pharmacovigilance to select and use the most appropriate algorithm for their specific needs. Key points: Three independently developed algorithms were designed to retrieve pregnancy-related adverse event reports and support research into pregnancy-specific safety concerns. By applying these algorithms to VigiBase and FAERS, we highlighted overlaps and differences in the reports they flag, reflecting heterogeneous scope and implementation. Awareness of these distinctions is essential to select and apply the most suitable algorithm for their specific needs.
- Open Access
- 19 June 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (11) , 1127-1136
Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance
Introduction There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.
- 19 June 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (11) , 1127-1136
Open AccessIdentification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance
Introduction There is a need to strengthen the evidence base regarding medication use during pregnancy and to facilitate the early detection of safety signals. EudraVigilance (EV) serves as the primary system for managing and analysing information concerning suspected adverse drug reactions (ADRs) within the European Economic Area. Despite its various functionalities, the current format for electronic submissions of safety reports lacks a specific data element indicating medicine exposure during pregnancy. Objective This paper aims to address the limitations of existing approaches by developing a rule-based algorithm in EV that more reliably identifies cases that are truly representative of an ADR during pregnancy. Methods The study utilised the standardised MedDRA query (SMQ) 'Pregnancy and neonatal topics' (PNT) as a benchmark for comparison. Recognising that the SMQ PNT also retrieves healthy pregnancy outcomes, contraceptive failure, failed abortifacients as well as ADRs not associated with pregnancy, a novel algorithm was tailored to improve the accuracy of identifying suspected ADRs occurring during pregnancy. Results Upon testing, the algorithm demonstrated superior performance, correctly predicting 90% of cases reporting an ADR during pregnancy, compared to 54% achieved by the SMQ PNT. The implementation of the algorithm in EV led to the retrieval of 202,426 cases. Conclusion The development and successful testing of the novel algorithm represents a step forward in pregnancy-specific signal detection in EV. Because signals associated with pregnancy may be diluted in a large database such as EV, this study lays the groundwork for future research to evaluate the effectiveness of disproportionality methods on a more refined subset of pregnancy-related ADR reports.
- Open Access
- 23 February 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (5) , 405-418
The Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally
The European Union (EU) regulatory network was at the forefront of the safety monitoring of COVID-19 vaccines during the pandemic. An unprecedented number of case reports of suspected adverse reactions after vaccination called for huge efforts for the assessment of this safety information, to ensure that any possible risks were detected and managed as early as possible, while ruling out coincidental but temporally related adverse health outcomes. We describe the role of the European Medicines Agency alongside the EU regulatory network in the safety monitoring of the COVID-19 vaccines, and provide an insight into challenges, particularities and outcomes of the scientific assessment and regulatory decisions in the complex, dynamic international environment of the pandemic. We discuss the flexible procedural tools that were used to ensure an expedited scientific assessment of safety issues, and subsequent updates of the product information (i.e., labelling) when available evidence (e.g., spontaneous reports, findings from observational studies and/or scientific literature) suggested that causal association is at least a reasonable possibility. The safety monitoring was accompanied by enhanced transparency measures, proactive communication, and easy access to information, which played a key role in public reassurance. The pandemic has been a powerful booster for worldwide collaboration, exchange of information and work-sharing. The safety monitoring of COVID-19 vaccines continues, and the lessons learned will be applied in future safety reviews, as well as future health emergencies.
- 23 February 2024
- Published by Springer Nature in Drug Safety
- Vol. 47 (5) , 405-418
Open AccessThe Role of the European Medicines Agency in the Safety Monitoring of COVID-19 Vaccines and Future Directions in Enhancing Vaccine Safety Globally
The European Union (EU) regulatory network was at the forefront of the safety monitoring of COVID-19 vaccines during the pandemic. An unprecedented number of case reports of suspected adverse reactions after vaccination called for huge efforts for the assessment of this safety information, to ensure that any possible risks were detected and managed as early as possible, while ruling out coincidental but temporally related adverse health outcomes. We describe the role of the European Medicines Agency alongside the EU regulatory network in the safety monitoring of the COVID-19 vaccines, and provide an insight into challenges, particularities and outcomes of the scientific assessment and regulatory decisions in the complex, dynamic international environment of the pandemic. We discuss the flexible procedural tools that were used to ensure an expedited scientific assessment of safety issues, and subsequent updates of the product information (i.e., labelling) when available evidence (e.g., spontaneous reports, findings from observational studies and/or scientific literature) suggested that causal association is at least a reasonable possibility. The safety monitoring was accompanied by enhanced transparency measures, proactive communication, and easy access to information, which played a key role in public reassurance. The pandemic has been a powerful booster for worldwide collaboration, exchange of information and work-sharing. The safety monitoring of COVID-19 vaccines continues, and the lessons learned will be applied in future safety reviews, as well as future health emergencies.
- Open Access
- 6 February 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (6) , 1223-1234
Safety Monitoring of COVID‐19 Vaccines: Perspective from the European Medicines Agency
Prior to deployment of coronavirus disease 2019 (COVID‐19) vaccines in the European Union in 2021, a high vaccine uptake leading to an unprecedented volume of safety data from spontaneous reports and real‐world evidence, was anticipated. The European Medicines Agency (EMA) implemented specific activities to ensure enhanced monitoring of emerging vaccine safety information, including intensive monitoring of reports of adverse events of special interest and the use of observed‐to‐expected analyses. The EMA also commissioned several independent observational studies using a large network of electronic healthcare databases and primary data collection via mobile and web‐based applications. This preparedness was key for two high‐profile safety signals: thrombosis with thrombocytopenia syndrome (TTS), a new clinical entity associated with adenovirus‐vectored vaccines, and myocarditis/pericarditis with messenger RNA vaccines. With no existing case definition nor background rates, the signal of TTS posed particular challenges. Nevertheless, it was rapidly identified, evaluated, contextualized and the risk minimized thanks to close surveillance and an efficient use of available evidence, clinical expertise and flexible regulatory tools. The two signals illustrated the complementarity between spontaneous and real‐world data, the former enabling rapid risk identification and communication, the latter enabling further characterization. The COVID‐19 pandemic has tremendously enhanced the development of tools and methods to harness the unprecedented volume of safety data generated for the vaccines. Areas for further improvement include the need for better and harmonized data collection across Member States (e.g., stratified vaccine exposure) to support signal evaluation in all population groups, risk contextualization, and safety communication.
- 6 February 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 113 (6) , 1223-1234
Open AccessSafety Monitoring of COVID‐19 Vaccines: Perspective from the European Medicines Agency
Prior to deployment of coronavirus disease 2019 (COVID‐19) vaccines in the European Union in 2021, a high vaccine uptake leading to an unprecedented volume of safety data from spontaneous reports and real‐world evidence, was anticipated. The European Medicines Agency (EMA) implemented specific activities to ensure enhanced monitoring of emerging vaccine safety information, including intensive monitoring of reports of adverse events of special interest and the use of observed‐to‐expected analyses. The EMA also commissioned several independent observational studies using a large network of electronic healthcare databases and primary data collection via mobile and web‐based applications. This preparedness was key for two high‐profile safety signals: thrombosis with thrombocytopenia syndrome (TTS), a new clinical entity associated with adenovirus‐vectored vaccines, and myocarditis/pericarditis with messenger RNA vaccines. With no existing case definition nor background rates, the signal of TTS posed particular challenges. Nevertheless, it was rapidly identified, evaluated, contextualized and the risk minimized thanks to close surveillance and an efficient use of available evidence, clinical expertise and flexible regulatory tools. The two signals illustrated the complementarity between spontaneous and real‐world data, the former enabling rapid risk identification and communication, the latter enabling further characterization. The COVID‐19 pandemic has tremendously enhanced the development of tools and methods to harness the unprecedented volume of safety data generated for the vaccines. Areas for further improvement include the need for better and harmonized data collection across Member States (e.g., stratified vaccine exposure) to support signal evaluation in all population groups, risk contextualization, and safety communication.